DeDora Capital’s iShares Biotechnology ETF IBB Stock Holding History

DeDora Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-429	Closed	-$56K	–	232
2022 Q1	$56K	Sell	429 -53,638	-99%	-$6.99M	0.02%	157
2021 Q4	$24.8M	Buy	+54,067	New	+$8.37M	14.08%	1
2020 Q1	–	Sell	-156	Closed	-$19K	–	96
2019 Q4	$19K	Buy	+156	New	+$17.4K	0.01%	105

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

DeDora Capital's IBB Position: Q2 2022 in Review

DeDora Capital sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 429 shares — an estimated $56K sold.

DeDora Capital first reported a position in IBB in Q4 2019 and held it in 3 quarters. The position peaked at $24.8M in Q4 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

DeDora Capital reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
DeDora Capital sold 429 iShares Biotechnology ETF shares in Q2 2022, an estimated $56K.
DeDora Capital first reported a position in iShares Biotechnology ETF in Q4 2019 and held it in 3 quarters.
DeDora Capital's iShares Biotechnology ETF position peaked at $24.8M in Q4 2021.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.